Alphabet’s AI Biotech Just Made a Massive $2.1B Bet on Drug Design and Development
A quiet revolution is underway in the Drug Design and Development industry, with investors pouring money into this innovative and growing sector.
In a revolutionary step, Isomorphic Labs, an Alphabet-backed company currently attracting attention in the Biotechnology industry, has made a massive move that could mark a turning point in AI-driven Drug Discovery.
Over the past few developmental years, people have become increasingly excited about AI (Artificial Intelligence) in the Healthcare sector. And it appears the transformation of Drug Discovery using AI is just beginning in this innovative and advancing Biotechnology sector.
There has been considerable excitement around AI in the Healthcare and Biotechnology industries, especially in Drug Design and Development.
It was recently announced that Isomorphic Labs, an AI-backed London-based company, has raised an astounding $2.1 billion in a Series B funding round.
Major Investors Join the Funding Round
The Series B funding round was led by Thrive Capital, with participation from Alphabet and Google’s venture arm, GV. Several new investors also joined the round, including MGX, Temasek, CapitalG, and the U.K. government’s AI-focused investment fund.
This latest funding comes only a year after Isomorphic Labs raised $600 million in its first external funding round, showing how strongly investors believe in the future of AI-driven Drug Design and Development.
Building a Unified AI Drug Design Engine
Isomorphic Labs was founded in 2021 by Demis Hassabis under Alphabet. The company was founded with a mission to develop multiple AI models that together can form a unified drug-design engine capable of improving the discovery and development of drugs.
Traditional Drug Discovery is often expensive, time-consuming, and highly complex. Isomorphic Labs aims to simplify this process through advanced AI systems that can better predict molecular structures and interactions. The company believes this Technology can significantly improve Drug Design and Development by helping Researchers identify promising drug candidates more efficiently.
AlphaFold 3 Supports AI-Based Research in Drug Design and Development
One of the company’s main Technologies is AlphaFold 3, an AI model developed by Google DeepMind and partners to help Scientists predict what molecules will look like, how they might interact, as well as discover novel drugs.
This Technology is of great importance to Modern Drug Design and Development, and understanding how drug molecules work (or interact or behave) is critical in developing novel drugs and further therapeutics. In essence, the use of AI to predict these molecular behaviors allows researchers and scientists to reduce the time required in Early-Stage Drug Discovery.
The newly raised massive capital will be applied to the advanced development of Isomorphic Labs’ AI Drug Design platform, known as “IsoDDE.” The company states that the investment will accelerate its Internal Drug pipeline towards entering the Clinic.
Partnerships With Leading Pharma Companies
Isomorphic Labs has already partnered with major Pharmaceutical companies such as Eli Lilly and Company & Novartis.
Both companies worked with Isomorphic Labs to use AlphaFold-based Technology for discovering small-molecule drugs against undisclosed Biological targets. These collaborations reflect the increasing role of AI in Drug Design and Development across the global Pharmaceutical industry.
Demis Hassabis on the Company’s Next Phase In AI Drug Design and Development
Speaking about the funding announcement, Demis Hassabis said the Series B investment would allow the company to scale its AI-powered Drug Design and Development platform and continue advancing its long-term mission to solve diseases through AI (Artificial Intelligence).
He highlighted the funding round as a strong vote of confidence from global investors in the company’s AI-first approach to Drug Discovery and Development.
Hassabis also stated that the company has now demonstrated that its Scientific approach is fundamentally sound and that the next focus will be scaling the Technology to its full potential.
Alphabet Highlights Isomorphic Labs’ Progress
Ruth Porat also commented on the funding announcement, saying that Isomorphic Labs has already made extraordinary progress in using AI to accelerate Drug Discovery.
According to Porat, the new investment will help speed up Research efforts and support the development of important medical treatments that could reach the market faster.
Growing Momentum for AI in Biotechnology
The latest investment in Isomorphic Labs reflects the growing global momentum behind AI-driven Drug Development. Pharmaceutical companies and investors are increasingly exploring technologies that can improve Research efficiency, lower development costs, and shorten timelines for discovering new medicines.
As AI becomes more deeply integrated into Biotechnology Research, companies like Isomorphic Labs are positioning themselves at the center of the next generation of Healthcare innovation and Drug Design and Development.
